Markets
A crowd of visitors at the Qualcomm ( Qualcomm is an...
A crowd of visitors at the Qualcomm exhibition area (Pradeep Gaur/Getty Images)

Qualcomm tumbles after releasing gloomy Q2 guidance thanks to memory chip supply crunch

Q1 results beat expectations, but the memory chip crunch looks to be weighing on the forward outlook.

Qualcomm is tumbling in after-hours trading after releasing an underwhelming Q3 sales outlook.

Shares were recently down 6%.

For its fiscal Q1, the seller of smartphone and other chips reported:

  • Sales of $12.25 billion (estimate: $12.2 billion, guidance for $11.8 billion to $12.6 billion).

  • Adjusted earnings per share of $3.50 (estimate: $3.41, guidance for $3.30 to $3.50).

For Q2, however, management said sales would range from $10.2 billion to $11 billion. Even the top end of that range is lower than the $11.2 billion consensus estimate. Its bottom-line outlook also disappointed, with earnings per share projected to range from $2.45 to $2.65, while the consensus estimate was at $2.89.

Coming into this report, there were concerns about whether smartphone supply and demand would hold up amid rising memory chip prices, with sellers incentivized to meet demand from AI customers first. Those fears look to be warranted.

“While our near-term handsets outlook is impacted by industry-wide memory supply constraints, we are encouraged by end-consumer demand for premium and high-tier smartphones, and remain on track to achieve our fiscal 2029 revenue goals,” President and CEO Cristiano Amon said.

The earnings presentation accompanying these results indicated that several original equipment manufacturers, especially in China, have taken steps “to reduce their handset build plans and channel inventory” in light of the “industry-wide memory shortage and price increases,” which “are likely to define the overall scale of the handset industry through the fiscal year.”

During the quarter, Qualcomm laid out plans to capitalize on the AI boom by announcing new chips for data centers, with Saudi Arabia’s HUMAIN lined up as the first major customer.

More Markets

See all Markets
markets

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

markets

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lillys diabetes and weight-loss drugs have outsold Novos, and that gap is expected to widen this year.

markets

Crypto crumble smokes bitcoin-sensitive stocks and speculative tech

It’s a rough day out there, with the pain in the crypto markets being felt among select subgroups of US equities. Shortly before 2 p.m. ET on Wednesday, here’s a snapshot of where some of the worst pinches are.

There is some overlap between some of these baskets: for instance, bitcoin treasury company Strategy figures both in the “bitcoin sensitive” and “meme” basket. But in general it’s just a pretty ugly day for some of the more speculative corners of the stock market.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.